FindTrial
Sign In

Evaluation of antibody and cytokine detection in tears of COVID-19 patients

SARS-CoV-2 in ocular secretions: Role of inflammatory mediators in tears of COVID-19 patients to detect biomarkers of disease severity and prognosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/11/028813
Enrollment
120
Registered
2020-11-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B342- Coronavirus infection, unspecified

Interventions

Control Intervention1: NIL: NIL

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: COVID-19 positive patients will be recruited, including both adults and children. A total of 90 COVID patients [mild disease (30 patients), moderate (30 patients) and severe (30 patients)] will be enrolled, as per the ICMR criteria, along with 30 healthy controls.

Exclusion criteria

Exclusion criteria: Patients not willing to give consent

Design outcomes

Primary

MeasureTime frame
Detection of cytokines and anti COVID antibodies in tear and blood samples of COVID-19 patientsTimepoint: 6-8 months—

Secondary

MeasureTime frame
Identification of tear biomarkers in COVID-19 patientsTimepoint: 6-8 months—

Countries

India

Contacts

Public ContactReema Bansal

PGIMER

drreemab@rediffmail.com09878011253

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026